Evidence map›Paper›PMID 33727342›Full record

ArticleMolecular cancer research : MCR2021

Proteomic Analysis of Src Family Kinase Phosphorylation States in Cancer Cells Suggests Deregulation of the Unique Domain.

Ana Ruiz-Saenz, Farima Zahedi, Elliott Peterson, Ashley Yoo, Courtney A Dreyer, Danislav S Spassov, Juan Oses-Prieto, Alma Burlingame, Mark M Moasser

Open access · bronzeAbstract read
In one paragraph

Article in Molecular cancer research : MCR, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
0.8field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 3 countries.

Ana Ruiz-Saenz *Departments of Cell Biology & Medical Oncology, Erasmus Medical Center, Rotterdam, the Netherlands.ORCID 0000-0001-6033-6153
Farima Zahedi *Department of Medicine, University of California, San Francisco, San Francisco, California.
Elliott PetersonDepartment of Medicine, University of California, San Francisco, San Francisco, California.ORCID 0000-0002-8730-786X
Ashley YooDepartment of Medicine, University of California, San Francisco, San Francisco, California.ORCID 0000-0001-6702-0848
Courtney A DreyerDepartment of Biochemistry and Molecular Medicine, University of California, Davis, Davis, California.
Danislav S SpassovFaculty of Pharmacy, Medical University of Sofia, Sofia, Bulgaria.
Juan Oses-PrietoDepartment of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, California.
Alma BurlingameDepartment of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, California.
Mark M MoasserDepartment of Medicine, University of California, San Francisco, San Francisco, California. mark.moasser@ucsf.edu.
University of California, San Francisco · USErasmus MC · NLMedical University of Sofia · BGUniversity of California, Davis · US

Funding

Bio-Organic Biomedical Mass Spectromy ResourceP41GM103481 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BURLINGAME, ALMA L · 2012 to 2015
$6.4M
Understanding resistance to HER family tyrosine kinase inhibitorsR01CA122216 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MOASSER, MARK M · 2007 to 2017
$3.0M
Purchase of Q-Exactive Mass SpectrometerS10OD016229 · OD · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BURLINGAME, ALMA L · 2013 to 2013
$507k
NCI NIH HHS R01 CA122216NIGMS NIH HHS P41 GM103481NIH HHS S10 OD016229
6 · The paper itself

Abstract

The Src family kinases (SFK) are homologs of retroviral oncogenes, earning them the label of proto-oncogenes. Their functions are influenced by positive and negative regulatory tyrosine phosphorylation events and inhibitory and activating intramolecular and extramolecular interactions. This regulation is disrupted in their viral oncogene counterparts. However, in contrast to most other proto-oncogenes, the genetic alteration of these genes does not seem to occur in human tumors and how and whether their functions are altered in human cancers remain to be determined. To look for proteomic-level alterations, we took a more granular look at the activation states of SFKs based on their two known regulatory tyrosine phosphorylations, but found no significant differences in their activity states when comparing immortalized epithelial cells with cancer cells. SFKs are known to have other less well-studied phosphorylations, particularly within their unstructured N-terminal unique domains (UD), although their role in cancers has not been explored. In comparing panels of epithelial cells with cancer cells, we found a decrease in S17 phosphorylation in the UD of Src in cancer cells. Dephosphorylated S17 favors the dimerization of Src that is mediated through the UD and suggests increased Src dimerization in cancers. These data highlight the important role of the UD of Src and suggest that a deeper understanding of proteomic-level alterations of the unstructured UD of SFKs may provide considerable insights into how SFKs are deregulated in cancers. IMPLICATIONS: This work highlights the role of the N-terminal UD of Src kinases in regulating their signaling functions and possibly in their deregulation in human cancers.

Indexed as

Binding SitesCell LineCell Line, TumorEnzyme ActivationEpithelial CellsHumansMass SpectrometryMicroscopy, FluorescenceMutationPhosphorylationProtein BindingProteomeProteomicsSerinesrc-Family KinasesProteomeSerinesrc-Family Kinases

Identifiers

PMID33727342
PMCPMC8178206
OpenAlexW3138955974

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.